Skip to content
FrontierPicks

Watchlist

KURA · Kura Oncology, Inc.

Conviction · LOW Earnings inflection Catalyst · Oncology & immunologyMedtech & diagnostics

Last analysed ·

Against its published line

Nothing is through its line on this close.

How to read this

The red mark is the published kill line — the price that would prove the pick wrong. The dot is where the name closed on 18 September 2026; a dot LEFT of the mark has closed through its line.

Distance is drawn on a square-root scale, so close calls get the room. Past 8% a row stops competing and reads well clear, with a hollow dot to say the figure is off the drawn scale. Rows run tightest first.

How a pick resolves

KURAKura Oncology, Inc.
$9.50
$11.73
+23.5%well clear

Resolved Graded and closed 2026-08-14 at low conviction — the published kill line did not fire. Coverage continued after the close; the read below is dated 2026-09-13 and is not part of the scored record.

Current thesis

The binary already fired: KOMZIFTI's 2025-11-13 approval and ~40% R/R NPM1 share are priced, and the $24–28 targets need a frontline Phase 3 that doesn't read until 2028. The tape is drifting — $10.39, lower third of the H1 range. A maturing special-situation biotech in a two-year catalyst gap; the ~2026-08-06 Q2 print is the next real read, not an accelerating setup.

Kill line

A weekly close below $9.50 breaks the post-approval consolidation base and loses the rising 200-day; confirmed if the ~2026-08-06 Q2 print shows KOMZIFTI revenue stalling near Q1's $5.8M, or the menin-inhibitor class flips to saturated as revumenib and bleximenib take frontline share.

Pick status

Played out resolved published kill line did not fire How this is scored →

Latest analysis and events for KURA —

As of 13 September 2026, the latest FrontierPicks analysis for Kura Oncology, Inc. (KURA): The binary already fired: KOMZIFTI's 2025-11-13 approval and ~40% R/R NPM1 share are priced, and the $24–28 targets need a frontline Phase 3 that doesn't read until 2028. The tape is drifting — $10.39, lower third of the H1 range. A maturing special-situation biotech in a two-year catalyst gap; the ~2026-08-06 Q2 print is the next real read, not an accelerating setup.

Kill line: A weekly close below $9.50 breaks the post-approval consolidation base and loses the rising 200-day; confirmed if the ~2026-08-06 Q2 print shows KOMZIFTI revenue stalling near Q1's $5.8M, or the menin-inhibitor class flips to saturated as revumenib and bleximenib take frontline share.

Most recent dated event on file: — catalyst 4d ago.

Current Thesis

Kura Oncology’s thesis is continued KOMZIFTI launch growth, with the next quarterly product-revenue report determining whether commercial progress survives the September price reversal. The case plays out if third-quarter product revenue exceeds the second quarter’s $9.1 million before a weekly close below $9.50 invalidates it. Kura reported that second-quarter figure on 2026-08-12, alongside approximately 115 new patient starts.

The substantive change since the 2026-09-03 note is Caspian Therapeutics. Kura’s 2026-09-09 filing records a $50 million subsidiary financing completed on 2026-09-08, including $4.3 million invested by Kura, which retained approximately 49.2% of outstanding capital. That financing adds separately funded diabetes research; it is not KOMZIFTI revenue. Kura Form 8-K

The life-cycle assessment is an inference: the narrative is maturing — the launch case dates to the 2026-08-12 results, while the adjusted close weakened from $13.11 on 2026-09-02 to $11.39 on 2026-09-11 despite the new subsidiary announcement. Caspian adds a dated scientific event, but its announcement presents preclinical evidence rather than human efficacy results. Caspian announcement, 2026-09-09

Bullish and bearish views on Kura Oncology, Inc.

The model's bull view on Kura Oncology, Inc. (KURA), in brief: The commercial launch grew. Kura’s 2026-08-12 results reported second-quarter KOMZIFTI product revenue of $9.1 million, up 57% sequentially, with approximately 115 new patient starts and more than 250 prescriptions. These are measured launch indicators; the short commercial… The bear view: The momentum condition already failed. The 2026-09-11 adjusted close of $11.39 finished below the $11.50 warning level identified in the 2026-09-03 note. The earlier continuation argument has weakened even though the published $9.50 thesis boundary remains unbreached at that… Both cases follow in full.

Bull Case

  • The commercial launch grew. Kura’s 2026-08-12 results reported second-quarter KOMZIFTI product revenue of $9.1 million, up 57% sequentially, with approximately 115 new patient starts and more than 250 prescriptions. These are measured launch indicators; the short commercial history cannot establish a durable acceleration trend.
  • Management reported broader initial adoption. In its 2026-08-12 update, Kura claimed a majority of new patient starts within the menin-inhibitor class for relapsed or refractory NPM1-mutated acute myeloid leukemia. This is company-reported market share, not independently verified prescription research.
  • Diabetes development has dedicated funding. Caspian’s financing was led by BVF Partners with Eli Lilly participating, according to Kura’s 2026-09-09 announcement. Participation establishes financing support; it does not establish clinical efficacy. Company announcement

Bear Case

  • The momentum condition already failed. The 2026-09-11 adjusted close of $11.39 finished below the $11.50 warning level identified in the 2026-09-03 note. The earlier continuation argument has weakened even though the published $9.50 thesis boundary remains unbreached at that reference close.
  • Commercial scale remains limited. Kura’s 2026-08-12 results paired $9.1 million of second-quarter product revenue with a $68.3 million net loss. Total revenue includes collaboration revenue, making the product line the cleaner test of launch demand.
  • Diabetes evidence remains preclinical. The 2026-09-09 announcement describes animal and human-islet models and gives no fixed date for submitting the investigational new drug application. Those observations do not establish treatment benefit in patients. Company announcement

Setup & Price Structure

The 2026-09-11 adjusted daily close was $11.39, against a 52-week high of $13.59; the supplied market series places the shares 16.2% below that high and up 25.9% over three months. The 14-day relative strength index (RSI) measured 45.3, compared with 72.3 on 2026-09-02. These observations show diminished momentum; they do not establish a new base.

Institutional attention was scheduled around the 2026-09-08 Wells Fargo, 2026-09-09 Cantor and 2026-09-16 Morgan Stanley conferences. That calendar measures clustered exposure, not attendance, fund flows or ownership concentration. No quantified retail-sentiment, short-interest or current moving-average series is available here, so crowding and distance above moving-average support cannot be established. Kura conference announcement, 2026-09-01

Catalyst Calendar (next 30 days)

  • 2026-09-29 — European Association for the Study of Diabetes annual meeting. Kura scheduled an oral presentation of KO-7246 preclinical results. This provides a dated examination of the subsidiary’s scientific rationale, without resolving human efficacy. Kura’s 2026-09-09 announcement
  • ~2026-11-10, est. Third-quarter financial results. This later event is the commercial thesis test: product revenue above the $9.1 million reported on 2026-08-12 would satisfy the stated growth case. The date remains an estimate based on the 2026-05-12 and 2026-08-12 reporting cadence, not a confirmed appointment.

Elapsed catalysts

  • 2026-09-16 — Morgan Stanley Global Healthcare Conference, 7:45 a.m. Eastern time. Management has a scheduled presentation; the announcement contains no commitment to release clinical results. Kura’s 2026-09-01 schedule (passed 4d ago)

What Would Change Our Mind

Failure of the longer recovery structure would end the case: a weekly close below $9.50 breaches the research boundary published on 2026-09-03. No current moving-average measurement supports attaching a moving-average claim to that level. Independently, third-quarter KOMZIFTI product revenue at or below the second quarter’s $9.1 million would refute continued sequential launch growth; collaboration payments would not reverse that finding.

The maturing assessment would change if fresh clinical evidence coincided with a weekly close above the $13.59 reference high recorded as of 2026-09-11. A conference appearance alone does not satisfy that condition.

Correlation Notes

This remains a single-company setup. The 2026-08-12 KOMZIFTI results and the 2026-09-09 Caspian financing announcement concern different sources of company value, but no return-correlation dataset establishes how either relates to broader oncology or diabetes equities. Lilly’s participation in Caspian’s financing is a corporate relationship, not evidence that Kura tracks Lilly’s shares. Caspian announcement

Notes

  • Ziftomenib is partnered with Kyowa Kirin (Nov 2024, up to $1.161B, 50/50 US profit share) — US economics are shared and ex-US value accrues to the partner.
  • Reported total revenue mixes KOMZIFTI product sales with lumpy Kyowa collaboration revenue; the launch signal is the product line alone ($9.1M in Q2 2026).
  • Company guides collaboration revenue of $45–55M for 2026 and $90–110M for each of 2027 and 2028 (Q2 release, 2026-08-12).
  • The stated runway through the 2028 KOMET-017 topline assumes $180M of anticipated Kyowa Kirin payments arrive on schedule.
  • The 2H 2026 KOMET-007 quizartinib/7+3 and KOMET-008 gilteritinib datasets have no announced venue or date as of 2026-09-03.
  • Reporting cadence: Q1 2026 on 2026-05-12, Q2 2026 on 2026-08-12; Q3 is therefore estimated for early-to-mid November, not confirmed.

Related · shared themes

See also · stocks to watch